Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided...

Area of Science:

• Hepatology and Virology
• Clinical Trial Data Analysis
• Viral Load Quantification

Background:

• Retrospective analyses of boceprevir and telaprevir phase 3 trials were conducted.
• Clinical relevance of detected but not quantifiable hepatitis C virus (HCV) genotype 1 RNA during treatment was assessed.

Purpose of the Study:

• To emphasize the importance of precise and standard terminology for reporting low-level HCV RNA results.
• To ensure consistent data collection across clinical trials and optimize virologic response-guided treatment decisions in clinical practice.

Main Methods:

• Retrospective analysis of phase 3 clinical trial data for boceprevir and telaprevir.
• Evaluation of the clinical significance of low-level HCV RNA detection during antiviral therapy.
• Clarification of terminology for unquantifiable HCV RNA in the context of current quantitative assays.

Main Results:

• Detected but not quantifiable HCV RNA during treatment holds clinical relevance.
• The terms "target detected" or "target not detected" accurately classify qualitative HCV RNA levels.
• Imprecise terms like "undetectable" or "below limit of detection" can be misinterpreted.

Conclusions:

• Standardized and precise terminology for low-level HCV RNA is essential for clinical trial data and patient management.
• Classifying unquantifiable HCV RNA as "target detected" or "target not detected" aids in treatment decision-making.
• Avoiding ambiguous terms ensures consistent interpretation and optimal patient care in hepatitis C treatment.